CFO
Ona Therapeutics
Ona Therapeutics is a biopharmaceutical company developing first-in-class antibody-drug conjugates (ADCs) for patients with advanced, treatment-refractory cancer. The company identifies novel therapeutic targets from real-world samples of refractory patients, then engineers precision ADCs with optimized pharmacokinetics and tolerability. Its pipeline includes multiple ADC candidates targeting breast cancer and prevalent solid tumors, including a dual-payload ADC.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Updated 5 days ago
Funding
Raised to date
$120.9MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 3 rounds
+5$86.6M · Series B
Announced Jun 2026 · from article date
Disclosed cumulative: $120.9M
3/3
RoundDateAmountValuationInvestors
Founders
Product
Problem
Patients with advanced, treatment-refractory cancer often exhaust standard therapies and are left without effective treatment options. A limited understanding of how cancers evolve after multiple lines of therapy hampers the discovery of new, actionable targets.
Solution
Ona Therapeutics focuses on creating first-in-class antibody-drug conjugates (ADCs) that target novel antigens identified from the biology of refractory tumors. By partnering with academic and clinical researchers, the company isolates molecular changes that arise after standard of care treatment and selects targets beyond traditional tumor antigens. These targets are incorporated into precision-engineered ADCs and antibody therapeutics using advanced protein-engineering techniques to optimize pharmacokinetics and tolerability. The streamlined development pipeline advances only candidates with strong preclinical activity and safety profiles, aiming to deliver new treatment options for patients who have exhausted existing therapies.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking novel ADC candidates, as well as oncologists and clinical researchers focused on treatment-refractory solid tumors.
Features
- Target discovery pipeline that leverages real-world samples from refractory cancer patients to identify novel molecular targets
- Custom antibody engineering platform for optimizing binding affinity, pharmacokinetics, and payload delivery
- Precision ADC design with flexible payload options, including dual-payload configurations
- Integrated development process that accelerates preclinical validation and IND-enabling activities
- Partnerships with leading academic and clinical groups to access privileged biological insights
- Pipeline includes ONA-255 ADC (breast cancer and solid tumors), ONA-389 ADC (prevalent solid tumors), ONA-418 dual-payload ADC (prevalent solid tumors), and a next-generation ADC candidate